share_log

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Anson Funds Management LP(4.9%),Anson Management GP LLC(4.9%), etc.

SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Anson Funds Management LP(4.9%),Anson Management GP LLC(4.9%), etc.

SC 13G/A：超过5%持股股东披露文件(修正)-Anson Funds Management LP(4.9%),Anson Management GP LLC(4.9%)等
美股SEC公告 ·  2024/11/14 18:06

Moomoo AI 已提取核心信息

An amendment to Schedule 13G has been filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a change in their holdings of ZyVersa Therapeutics, Inc. common stock. The filing, dated September 30, 2024, reports that these entities and individuals collectively own 54,054 shares, representing 4.9% of the company's issued common stock. This stake is held by a private fund for which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors, with the power to direct voting and disposition of the shares. The amendment restates the previously filed Schedule 13G and provides updated information on the beneficial ownership, including the address and organizational details of the reporting persons. The filing also certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of ZyVersa Therapeutics, Inc.
An amendment to Schedule 13G has been filed with the SEC by Anson Funds Management LP, Anson Management GP LLC, Tony Moore, Anson Advisors Inc., Amin Nathoo, and Moez Kassam, indicating a change in their holdings of ZyVersa Therapeutics, Inc. common stock. The filing, dated September 30, 2024, reports that these entities and individuals collectively own 54,054 shares, representing 4.9% of the company's issued common stock. This stake is held by a private fund for which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors, with the power to direct voting and disposition of the shares. The amendment restates the previously filed Schedule 13G and provides updated information on the beneficial ownership, including the address and organizational details of the reporting persons. The filing also certifies that the shares were acquired in the ordinary course of business and not for the purpose of changing or influencing the control of ZyVersa Therapeutics, Inc.
Anson基金管理有限合伙公司，Anson Management GP有限责任合伙公司，Tony Moore，Anson Advisors Inc.， Amin Nathoo和Moez Kassam已向证券交易委员会提交了对于ZyVersa Therapeutics，Inc.普通股持股变动的第13G表修正案。该文件于2024年9月30日提交，报告了这些实体和个人共同拥有54,054股，占公司已发行普通股的4.9％。该股权由一家私人基金持有，Anson Funds Management LP和Anson Advisors Inc.作为共同投资顾问，具有指导表决和股份处置权。该修正案重新声明了先前提交的第13G表，并提供了有关受益所有权的更新信息，包括报告人的地址和组织细节。该文件还确认这些股份是在业务常规过程中收购的，而非用于改变或影响ZyVersa Therapeutics，Inc.的控制权。
Anson基金管理有限合伙公司，Anson Management GP有限责任合伙公司，Tony Moore，Anson Advisors Inc.， Amin Nathoo和Moez Kassam已向证券交易委员会提交了对于ZyVersa Therapeutics，Inc.普通股持股变动的第13G表修正案。该文件于2024年9月30日提交，报告了这些实体和个人共同拥有54,054股，占公司已发行普通股的4.9％。该股权由一家私人基金持有，Anson Funds Management LP和Anson Advisors Inc.作为共同投资顾问，具有指导表决和股份处置权。该修正案重新声明了先前提交的第13G表，并提供了有关受益所有权的更新信息，包括报告人的地址和组织细节。该文件还确认这些股份是在业务常规过程中收购的，而非用于改变或影响ZyVersa Therapeutics，Inc.的控制权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Corcept医疗
    CORT
    -- 114.220
    ABVC BioPharma
    ABVC
    -- 1.0600
    bluebird bio
    BLUE
    -- 4.880
    NLS Pharmaceutics
    NLSP
    -- 1.5400
    DBV Technologies
    DBVT
    -- 6.820
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    FOMC维持利率但不确定性高企：美股后市走向如何？
    🎙️讨论 1. 美联储强调政策路径存在“高度不确定性”，你更关注利率预期变化还是经济数据对市场的短期影响？ 2. 若核心通胀维持高位，哪类板块更具交易机会——防御型股票还是科技成长股？ 展开
    联邦公开市场委员会新闻发布会，2025年3月19日